SLC5A2 and cardiac arrest: <b>Results:</b> After adjustment for comorbidities, SGLT2 inhibitor use was independently associated with lower all-cause mortality (6.15% vs. 9.34% HR 0.595; 95% CI 0.552-0.641; <i>p</i> < 0.001), TAVR (2.81% vs. 2.89% HR 0.835; 95% CI 0.746-0.934; <i>p</i> = 0.002), SAVR (1.28% vs. 1.90% HR 0.514; 95% CI 0.442-0.599; <i>p</i> < 0.001), cardiac arrest (0.82% vs. 1.21% HR 0.71; 95% CI 0.582-0.867; <i>p</i> < 0.001), and end-stage kidney disease (0.40% vs. 1.0% HR 0.292; 95% CI 0.222-0.384; <i>p</i> < 0.001).